Skip to main content
SpringerLink
Log in

Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat

  • Original Article
  • Anthracyclines, Daunorubicin, Daunorubicinol, Pharmacokinetics, Rat, Tissue Concentrations
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Recent evidence suggests that 13-hydroxy metabolites of anthracyclines may contribute to cardiotoxicity. This study was designed to determine the pharmacokinetics of daunorubicin and the 13-hydroxy metabolite daunorubicinol in plasma and tissues, including the heart. Fisher 344 rats received 5 mg kg−1 daunorubicin i.v. by bolus injection. Rats were killed at selected intervals for up to 1 week after daunorubicin administration for determination of concentrations of daunorubicin and daunorubicinol in the plasma, heart, liver, kidney, lung, and skeletal muscle. Peak concentrations of daunorubicin were higher than those of daunorubicinol in the plasma (133±7 versus 36±2 ng ml−1;P<0.05), heart (15.2±1.4 versus 3.4±0.4 μg g−1;P<0.05), and other tissues. However, the apparent elimination half-life of daunorubicinol was longer than that of daunorubicin in most tissues, including the plasma (23.1 versus 14.5 h) and heart (38.5 versus 19.3 h). In addition, areas under the concentration/time curves (AUC∞) obtained for daunorubicinol exceeded those found for daunorubicin in almost all tissues, with the ratios being 1.9 in plasma and 1.7 in the heart. The ratio of daunorubicinol to daunorubicin concentrations increased dramatically with time from <1 at up to 1 h to 87 at 168 h in cardiac tissue. Thus, following daunorubicin injection, cumulative exposure (AUC∞) to daunorubicinol was greater than that to daunorubicin in the plasma and heart. If daunorubicinol has equivalent or greater potency than daunorubicin in causing impairment of myocardial function, it may make an important contribution to the pathogenesis of cardiotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ahmed NK, Felsted RL, Bachur NR (1978) Heterogeneity of anthracycline antibiotic carbonyl reductases in mammalian liver. Biochem Pharmacol 27:2713

    Google Scholar 

  2. Boucek RJ Jr, Olson RD, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S (1987) The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. J Biol Chem 262:15851

    Google Scholar 

  3. Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88:168

    Google Scholar 

  4. Capps NE, Nidjikar S, Burns JH, Walker EJ, Dow JW (1985) Characterization of digoxin binding and daunorubicin uptake by isolated mature rat cardiac myocytes. Biochem Pharmacol 34:1957

    Google Scholar 

  5. Chen ZM, Colombo T, Conforti L, Grazia-Donelli M, Fiedorowicz RJ, Marchi S, Paolini A, Riva E, Zuanetti G, Latini R (1987) Effects of three anthracyclines and doxorubicin on the rat isolated heart. J Pharm Pharmacol 39:947

    Google Scholar 

  6. Cusack BJ, Tesnohlidek DA, Loseke VL, Vestal RE, Brenner DE, Olson RD (1988) Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cancer Chemother Pharmacol 22:294

    Google Scholar 

  7. Cusack BJ, Young SP, Loseke VL, Hurty MR, Olson RD (1992) Effect of low-protein diet on doxorubicin pharmacokinetics in the rabbit. Cancer Chemother Pharmacol 30:145

    Google Scholar 

  8. Cusack BJ, Young SP, Driskell J, Olson RD (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32:53

    Google Scholar 

  9. Cusack BJ, Mushlin PS, Voulelis LD, Li X, Boucek RJ Jr, Olson RD (1993) Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Toxicol Appl Pharmacol 118:177

    Google Scholar 

  10. Doroshow JW (1988) Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43:460

    Google Scholar 

  11. Freirich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey and man. Cancer Chemother Rep 50:219

    Google Scholar 

  12. Gibaldi M (1985) Biopharmaceutics and clinical pharmacokinetics, Lea & Febiger, Philadelphia, p 17

    Google Scholar 

  13. Harris RN, Doroshow JH (1985) Effect of doxorubicin-enhanced hydrogen peroxide and hydroxyl radical formation on calcium sequestration by cardiac sarcoplasmic reticulum. Biochem Biophys Res Commun 130:739

    Google Scholar 

  14. Kim DH, Landry AB, Lee YS, Katz AM (1989) Doxorubicininduced calcium release from cardiac sarcoplasmic reticulum vesicles. J Mol Cell Cardiol 21:433

    Google Scholar 

  15. Nooter K, Sonneveld S, Martens A (1985) Differences in the pharmacokinetics of daunomycin in normal and leukemic rats. Cancer Res 45:4020

    Google Scholar 

  16. Nooter K, Oostrum R, Deurloo J (1987) Effects of verapamil on the pharmacokinetics of daunomycin in the rat. Cancer Chemother Pharmacol 20:176

    Google Scholar 

  17. Olson RD, Brenner DE, Cusack BJ, Mushlin PS, Andrejuk T, Boucek RJ (1987) Effect of daunorubicinol on myocardial function. Proc Am Assoc Cancer Res 28:441

    Google Scholar 

  18. Olson RD, Mushlin PS, Brenner DE, Fleischer S, Cusack BJ, Chang BK, Boucek RJ Jr (1988) Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85:3585

    Google Scholar 

  19. Pessah IN, Durie EL, Schiedt MJ, Zimanyi I (1990) Anthraquinone-sensitized Ca2+-release channel from rat cardiac sarcoplasmic reticulum: possible receptor-mediated mechanism of doxorubicin cardiomyopathy. Mol Pharmacol 37:503

    Google Scholar 

  20. Robert J (1980) Extraction of anthracycline from biological fluids for HPLC evaluation. J Liquid Chromatgr 3:1561

    Google Scholar 

  21. Rusconi A, Fronzo G, Marco A. (1968) Distribution of tritiated daunomycin in normal rats. Cancer Chemother Rep 52:331

    Google Scholar 

  22. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia M (1977) Daunorubicin-induced cardiomyopathy in children and adults. A review of 110 cases. Am J Med 62:200

    Google Scholar 

  23. Zini G, Vicario GP, Lazzati M, Arcamone F (1986) Disposition and metabolism of [14-14C]4-demethoxydaunorubicin HCl (idarubicin) and [14-14C] daunorubicin HCl in the rat. Cancer Chemother Pharmacol 16:107

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gerontology and Clinical Pharmacology Research Unit, VA Medical Center, 500 West Fort Street, 83702-4598, Boise, ID, USA

    Barry J. Cusack, Stephan P. Young & Richard D. Olson

  2. School of Medicine, University of Washington, Seattle, Washington, USA

    Barry J. Cusack & Richard D. Olson

Authors
  1. Barry J. Cusack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephan P. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard D. Olson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cusack, B.J., Young, S.P. & Olson, R.D. Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat. Cancer Chemother. Pharmacol. 35, 213–218 (1995). https://doi.org/10.1007/BF00686550

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686550

Key words

Search

Navigation